United Therapeutics (UTHR) FCF Margin (2009 - 2026)

United Therapeutics has disclosed FCF Margin across 18 years of filings, most recently posting 26.25% for Q2 2026.

• In Q2 2026, FCF Margin rose 1003.0% year-over-year to 26.25%; the TTM figure through Jun 2026 stood at 34.65% (down 15.0% YoY), while the FY2025 annual figure was 32.7%, down 486.0% from the prior year.
• FCF Margin came in at 26.25% for Q2 2026 at United Therapeutics, down from 46.39% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 65.79% in Q1 2023 to a low of 10.33% in Q2 2023.
• Average FCF Margin over 5 years is 34.78%, with a median of 35.68% recorded in 2022.
• Year-over-year, FCF Margin soared 3869 bps in 2022 and slumped 1587 bps in 2024.
• Over 5 years, FCF Margin stood at 18.05% in 2022, then tumbled by 35 bps to 11.71% in 2023, then surged by 195 bps to 34.58% in 2024, then sank by 37 bps to 21.93% in 2025, then advanced by 20 bps to 26.25% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 26.25% in Q2 2026, 46.39% in Q1 2026, and 21.93% in Q4 2025.